Published in Expert Rev Mol Med on July 22, 2011
Cholesterol: its regulation and role in central nervous system disorders. Cholesterol (2012) 1.08
Ion-current-based proteomic profiling of the retina in a rat model of Smith-Lemli-Opitz syndrome. Mol Cell Proteomics (2013) 0.93
Cholesterol in brain disease: sometimes determinant and frequently implicated. EMBO Rep (2014) 0.88
Treatment of Smith-Lemli-Opitz syndrome and other sterol disorders. Am J Med Genet C Semin Med Genet (2012) 0.85
Hepatic isoprenoid metabolism in a rat model of Smith-Lemli-Opitz Syndrome. Lipids (2013) 0.79
From cholesterogenesis to steroidogenesis: role of riboflavin and flavoenzymes in the biosynthesis of vitamin D. Adv Nutr (2014) 0.78
Combining fetal sonography with genetic and allele pathogenicity studies to secure a neonatal diagnosis of Bardet-Biedl syndrome. Clin Genet (2012) 0.77
Evaluation of plasma cholestane-3β,5α,6β-triol and 7-ketocholesterol in inherited disorders related to cholesterol metabolism. J Lipid Res (2016) 0.77
Differential cytotoxic effects of 7-dehydrocholesterol-derived oxysterols on cultured retina-derived cells: Dependence on sterol structure, cell type, and density. Exp Eye Res (2016) 0.76
Smith-lemli-opitz syndrome: a case with annular pancreas. Case Rep Pediatr (2014) 0.75
Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science (2009) 8.80
Identification and evaluation of children with autism spectrum disorders. Pediatrics (2007) 7.54
Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. N Engl J Med (1994) 5.35
A NEWLY RECOGNIZED SYNDROME OF MULTIPLE CONGENITAL ANOMALIES. J Pediatr (1964) 4.60
The Smith-Lemli-Opitz syndrome. J Med Genet (2000) 3.05
Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery (1998) 2.99
Defective cholesterol biosynthesis in Smith-Lemli-Opitz syndrome. Lancet (1993) 2.79
Smith-Lemli-Opitz syndrome is caused by mutations in the 7-dehydrocholesterol reductase gene. Am J Hum Genet (1998) 2.62
A defective response to Hedgehog signaling in disorders of cholesterol biosynthesis. Nat Genet (2003) 2.29
Mutations in the Delta7-sterol reductase gene in patients with the Smith-Lemli-Opitz syndrome. Proc Natl Acad Sci U S A (1998) 2.22
Mutations in the human sterol delta7-reductase gene at 11q12-13 cause Smith-Lemli-Opitz syndrome. Am J Hum Genet (1998) 2.10
Clinical effects of cholesterol supplementation in six patients with the Smith-Lemli-Opitz syndrome (SLOS) Am J Med Genet (1997) 2.09
A novel, noninvasive method for the measurement of intestinal fat absorption. Gastroenterology (2004) 2.02
Diagnosis of Smith-Lemli-Opitz syndrome by gas chromatography/mass spectrometry of 7-dehydrocholesterol in plasma, amniotic fluid and cultured skin fibroblasts. Clin Chim Acta (1995) 1.99
Malformation syndromes caused by disorders of cholesterol synthesis. J Lipid Res (2010) 1.88
Smith-Lemli-Opitz syndrome: pathogenesis, diagnosis and management. Eur J Hum Genet (2008) 1.78
The teratology of autism. Int J Dev Neurosci (2005) 1.77
Smith-Lemli-Opitz syndrome: a variable clinical and biochemical phenotype. J Med Genet (1998) 1.65
Mutational spectrum in the Delta7-sterol reductase gene and genotype-phenotype correlation in 84 patients with Smith-Lemli-Opitz syndrome. Am J Hum Genet (2000) 1.61
Biochemical, phenotypic and neurophysiological characterization of a genetic mouse model of RSH/Smith--Lemli--Opitz syndrome. Hum Mol Genet (2001) 1.60
Clinical and biochemical spectrum of patients with RSH/Smith-Lemli-Opitz syndrome and abnormal cholesterol metabolism. Am J Med Genet (1997) 1.56
Behavior phenotype in the RSH/Smith-Lemli-Opitz syndrome. Am J Med Genet (2001) 1.55
7-Dehydrocholesterol-dependent proteolysis of HMG-CoA reductase suppresses sterol biosynthesis in a mouse model of Smith-Lemli-Opitz/RSH syndrome. J Clin Invest (2001) 1.55
Molecular cloning and expression of the human delta7-sterol reductase. Proc Natl Acad Sci U S A (1998) 1.49
Biological activities of 7-dehydrocholesterol-derived oxysterols: implications for Smith-Lemli-Opitz syndrome. J Lipid Res (2010) 1.44
The near universal presence of autism spectrum disorders in children with Smith-Lemli-Opitz syndrome. Am J Med Genet A (2006) 1.37
Markedly inhibited 7-dehydrocholesterol-delta 7-reductase activity in liver microsomes from Smith-Lemli-Opitz homozygotes. J Clin Invest (1995) 1.30
Biochemical and genetic aspects of 7-dehydrocholesterol reductase and Smith-Lemli-Opitz syndrome. Biochim Biophys Acta (2000) 1.30
In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res (1994) 1.28
Carrier frequency of the common mutation IVS8-1G>C in DHCR7 and estimate of the expected incidence of Smith-Lemli-Opitz syndrome. Mol Genet Metab (2001) 1.28
Oxysterols from free radical chain oxidation of 7-dehydrocholesterol: product and mechanistic studies. J Am Chem Soc (2010) 1.27
Identification of 7(8) and 8(9) unsaturated adrenal steroid metabolites produced by patients with 7-dehydrosterol-delta7-reductase deficiency (Smith-Lemli-Opitz syndrome). J Steroid Biochem Mol Biol (2002) 1.24
Residual cholesterol synthesis and simvastatin induction of cholesterol synthesis in Smith-Lemli-Opitz syndrome fibroblasts. Mol Genet Metab (2005) 1.24
Recent insights into the Smith-Lemli-Opitz syndrome. Clin Genet (2005) 1.23
DHCR7 nonsense mutations and characterisation of mRNA nonsense mediated decay in Smith-Lemli-Opitz syndrome. J Med Genet (2005) 1.22
Membrane cholesterol: a crucial molecule affecting interactions of microbial pathogens with mammalian cells. Infect Immun (2005) 1.22
Effects of cholesterol and simvastatin treatment in patients with Smith-Lemli-Opitz syndrome (SLOS). J Inherit Metab Dis (2007) 1.20
Neuroprotection by a bile acid in an acute stroke model in the rat. J Cereb Blood Flow Metab (2002) 1.19
Preputial gland tumor sterols. 3. A metabolic pathway from lanosterol to cholesterol. J Biol Chem (1960) 1.19
Retinal degeneration in a rodent model of Smith-Lemli-Opitz syndrome: electrophysiologic, biochemical, and morphologic features. Arch Ophthalmol (2004) 1.16
RSH/Smith-Lemli-Opitz syndrome: a multiple congenital anomaly/mental retardation syndrome due to an inborn error of cholesterol biosynthesis. Mol Genet Metab (2000) 1.14
Prenatal diagnosis of the RSH/Smith-Lemli-Opitz syndrome. Am J Med Genet (1999) 1.13
Cholesterol supplementation does not improve developmental progress in Smith-Lemli-Opitz syndrome. J Pediatr (2004) 1.12
Abnormal cholesterol metabolism in the Smith-Lemli-Opitz syndrome: report of clinical and biochemical findings in four patients and treatment in one patient. Am J Med Genet (1994) 1.12
Oxidized derivatives of 7-dehydrocholesterol induce growth retardation in cultured rat embryos: a model for antenatal growth retardation in the Smith-Lemli-Opitz syndrome. J Lipid Res (1999) 1.12
Cholesterol and bile acid replacement therapy in children and adults with Smith-Lemli-Opitz (SLO/RSH) syndrome. Am J Med Genet (1997) 1.11
Development and characterization of a hypomorphic Smith-Lemli-Opitz syndrome mouse model and efficacy of simvastatin therapy. Hum Mol Genet (2006) 1.11
Simvastatin. A new therapeutic approach for Smith-Lemli-Opitz syndrome. J Lipid Res (2000) 1.09
Smith-Lemli-Opitz syndrome and autism spectrum disorder. Am J Psychiatry (2007) 1.08
The implications of 7-dehydrosterol-7-reductase deficiency (Smith-Lemli-Opitz syndrome) to neurosteroid production. Steroids (2004) 1.08
Vitamin D status in patients affected by Smith-Lemli-Opitz syndrome. J Inherit Metab Dis (2005) 1.07
Maternal apo E genotype is a modifier of the Smith-Lemli-Opitz syndrome. J Med Genet (2004) 1.07
Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol (2003) 1.07
Lipidomic analysis of the retina in a rat model of Smith-Lemli-Opitz syndrome: alterations in docosahexaenoic acid content of phospholipid molecular species. J Neurochem (2007) 1.06
Reproducing abnormal cholesterol biosynthesis as seen in the Smith-Lemli-Opitz syndrome by inhibiting the conversion of 7-dehydrocholesterol to cholesterol in rats. J Clin Invest (1995) 1.05
Analysis of short-term behavioral effects of dietary cholesterol supplementation in Smith-Lemli-Opitz syndrome. Am J Med Genet A (2010) 1.05
Defective conversion of 7-dehydrocholesterol to cholesterol in cultured skin fibroblasts from Smith-Lemli-Opitz syndrome homozygotes. J Lipid Res (1995) 1.03
Light-induced exacerbation of retinal degeneration in a rat model of Smith-Lemli-Opitz syndrome. Exp Eye Res (2005) 1.03
Highly sensitive analysis of sterol profiles in human serum by LC-ESI-MS/MS. J Lipid Res (2008) 1.02
Sterol balance in the Smith-Lemli-Opitz syndrome. Reduction in whole body cholesterol synthesis and normal bile acid production. J Lipid Res (2000) 1.02
Abnormalities of cholesterol metabolism in autism spectrum disorders. Am J Med Genet B Neuropsychiatr Genet (2006) 1.02
Cholesta-5,7,9(11)-trien-3 beta-ol found in plasma of patients with Smith-Lemli-Opitz syndrome indicates formation of sterol hydroperoxide. J Lipid Res (1996) 1.01
Potential of sterol analysis by liquid chromatography-tandem mass spectrometry for the prenatal diagnosis of Smith-Lemli-Opitz syndrome. Clin Chem (2008) 0.99
Abnormal bile acids in the Smith-Lemli-Opitz syndrome. Am J Med Genet (1994) 0.98
Effects of dietary cholesterol and simvastatin on cholesterol synthesis in Smith-Lemli-Opitz syndrome. Pediatr Res (2009) 0.97
Nanostructure-initiator mass spectrometry (NIMS) imaging of brain cholesterol metabolites in Smith-Lemli-Opitz syndrome. Neuroscience (2010) 0.97
27-Hydroxylation of 7- and 8-dehydrocholesterol in Smith-Lemli-Opitz syndrome: a novel metabolic pathway. Steroids (2003) 0.97
MRI and 1H MRS findings in Smith-Lemli-Opitz syndrome. Neuroradiology (2003) 0.96
Characterization of placental cholesterol transport: ABCA1 is a potential target for in utero therapy of Smith-Lemli-Opitz syndrome. Hum Mol Genet (2008) 0.96
Incidence of Smith-Lemli-Opitz syndrome in Canada: results of three-year population surveillance. J Pediatr (2004) 0.95
Dehydrosteroid measurements in maternal urine or serum for the prenatal diagnosis of Smith-Lemli-Opitz syndrome (SLOS). Am J Med Genet A (2007) 0.95
Evidence for requirement of NADPH-cytochrome P450 oxidoreductase in the microsomal NADPH-sterol Delta7-reductase system. Arch Biochem Biophys (2000) 0.95
Oxysterols in the circulation of patients with the Smith-Lemli-Opitz syndrome: abnormal levels of 24S- and 27-hydroxycholesterol. J Lipid Res (2001) 0.95
Cholesterol biosynthesis from birth to adulthood in a mouse model for 7-dehydrosterol reductase deficiency (Smith-Lemli-Opitz syndrome). Steroids (2007) 0.95
Cholesterol biosynthesis from lanosterol. A concerted role for Sp1 and NF-Y-binding sites for sterol-mediated regulation of rat 7-dehydrocholesterol reductase gene expression. J Biol Chem (2001) 0.94
Teratogenic effect of an inhibitor of cholesterol synthesis (AY 9944) in rats: correlation with maternal cholesterolemia. J Nutr (1980) 0.94
Quantitative proteomics analysis of inborn errors of cholesterol synthesis: identification of altered metabolic pathways in DHCR7 and SC5D deficiency. Mol Cell Proteomics (2010) 0.94
A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. J Lipid Res (2001) 0.94
7-Dehydrocholesterol down-regulates cholesterol biosynthesis in cultured Smith-Lemli-Opitz syndrome skin fibroblasts. J Lipid Res (1998) 0.94
Normal cognition and behavior in a Smith-Lemli-Opitz syndrome patient who presented with Hirschsprung disease. Am J Med Genet A (2003) 0.94
Smith-Lemli-Opitz syndrome. J Am Acad Child Adolesc Psychiatry (2001) 0.94
Novel mutations in the 7-dehydrocholesterol reductase gene of 13 patients with Smith--Lemli--Opitz syndrome. Ann Hum Genet (2001) 0.93
Cholesterol supplementation with egg yolk increases plasma cholesterol and decreases plasma 7-dehydrocholesterol in Smith-Lemli-Opitz syndrome. Am J Med Genet (2000) 0.93
Behavioral phenotype of RSH/Smith-Lemli-Opitz syndrome. Ment Retard Dev Disabil Res Rev (2000) 0.93
Cholesterol deficit but not accumulation of aberrant sterols is the major cause of the teratogenic activity in the Smith-Lemli-Opitz syndrome animal model. J Lipid Res (2000) 0.92
Changes in serum sterols of rats treated with 7-dehydrocholesterol-delta 7-reductase inhibitors: comparison to levels in humans with Smith-Lemli-Opitz syndrome. J Lipid Res (1996) 0.92
Where does fetal and embryonic cholesterol originate and what does it do? Annu Rev Nutr (2008) 0.92
Teratogenic action and embryo lethality of AY 9944R. Prevention by a hypercholesterolemia-provoking diet. Teratology (1979) 0.92
Role of cholesterol in embryonic development. Am J Clin Nutr (2000) 0.91
Direct analysis of filter paper blood specimens for identification of Smith-Lemli-Opitz syndrome using time-of-flight secondary ion mass spectrometry. Am J Med Genet (1997) 0.91
Photosensitivity associated with the Smith-Lemli-Opitz syndrome. Br J Dermatol (1998) 0.90
Fetal Smith-Lemli-Opitz syndrome can be detected accurately and reliably by measuring amniotic fluid dehydrocholesterols. Prenat Diagn (1998) 0.90
Smith-Lemli-Opitz syndrome: the first malformation syndrome associated with defective cholesterol synthesis. Mol Genet Metab (2000) 0.90
Ultraviolet A sensitivity in Smith-Lemli-Opitz syndrome: Possible involvement of cholesta-5,7,9(11)-trien-3 beta-ol. Free Radic Biol Med (2006) 0.89
Smith-Lemli-Opitz syndrome: treatment with cholesterol and bile acids. Neuropediatrics (1996) 0.89
Bile acid synthesis in the Smith-Lemli-Opitz syndrome: effects of dehydrocholesterols on cholesterol 7alpha-hydroxylase and 27-hydroxylase activities in rat liver. J Lipid Res (1999) 0.88
7-Dehydrocholesterol enhances ultraviolet A-induced oxidative stress in keratinocytes: roles of NADPH oxidase, mitochondria, and lipid rafts. Free Radic Biol Med (2006) 0.88
Alteration of retinal rod outer segment membrane fluidity in a rat model of Smith-Lemli-Opitz syndrome. J Lipid Res (2008) 0.88
Dehydro-oestriol and dehydropregnanetriol are candidate analytes for prenatal diagnosis of Smith-Lemli-Opitz syndrome. Prenat Diagn (2001) 0.88
Pompe disease diagnosis and management guideline. Genet Med (2006) 3.03
Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet (2013) 1.82
Effects of dietary cholesterol on plasma lipoproteins in Smith-Lemli-Opitz syndrome. Pediatr Res (2004) 1.57
Osteogenesis imperfecta: recent findings shed new light on this once well-understood condition. Genet Med (2009) 1.55
Genetic Counseling and Screening of Consanguineous Couples and Their Offspring: Recommendations of the National Society of Genetic Counselors. J Genet Couns (2002) 1.51
"I'm fine; I'm just waiting for my disease": the new and growing class of presymptomatic patients. Neurology (2011) 1.43
Missense mutations in CRELD1 are associated with cardiac atrioventricular septal defects. Am J Hum Genet (2003) 1.42
The near universal presence of autism spectrum disorders in children with Smith-Lemli-Opitz syndrome. Am J Med Genet A (2006) 1.37
Mutations in FKBP10, which result in Bruck syndrome and recessive forms of osteogenesis imperfecta, inhibit the hydroxylation of telopeptide lysines in bone collagen. Hum Mol Genet (2012) 1.29
Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev (2008) 1.29
Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force. Pediatrics (2007) 1.25
Mutations in PPIB (cyclophilin B) delay type I procollagen chain association and result in perinatal lethal to moderate osteogenesis imperfecta phenotypes. Hum Mol Genet (2011) 1.23
Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study. J Magn Reson Imaging (2004) 1.12
Cholesterol supplementation does not improve developmental progress in Smith-Lemli-Opitz syndrome. J Pediatr (2004) 1.12
Improved growth and nutrition status in children with methylmalonic or propionic acidemia fed an elemental medical food. Mol Genet Metab (2003) 1.08
Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study. Orphanet J Rare Dis (2012) 1.06
A membrane defect in the pathogenesis of the Smith-Lemli-Opitz syndrome. J Lipid Res (2005) 1.06
Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP). J Inherit Metab Dis (2011) 1.04
Age-related working memory impairments in children with prefrontal dysfunction associated with phenylketonuria. J Int Neuropsychol Soc (2002) 1.03
Skeletal changes in epidermal nevus syndrome: does focal bone disease harbor clues concerning pathogenesis? Am J Med Genet A (2005) 1.00
Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): data from the Hunter Outcome Survey. Genet Med (2010) 0.99
Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev (2014) 0.98
Central nervous system stem cell transplantation for children with neuronal ceroid lipofuscinosis. J Neurosurg Pediatr (2013) 0.98
Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease. J Alzheimers Dis (2008) 0.98
Age-related decline in the microstructural integrity of white matter in children with early- and continuously-treated PKU: a DTI study of the corpus callosum. Mol Genet Metab (2010) 0.98
Effects of dietary cholesterol and simvastatin on cholesterol synthesis in Smith-Lemli-Opitz syndrome. Pediatr Res (2009) 0.97
ESI-MS/MS quantification of 7alpha-hydroxy-4-cholesten-3-one facilitates rapid, convenient diagnostic testing for cerebrotendinous xanthomatosis. Clin Chim Acta (2009) 0.97
Hypomorphic temperature-sensitive alleles of NSDHL cause CK syndrome. Am J Hum Genet (2010) 0.97
Liquid chromatography-tandem mass spectrometry determination of plasma 24S-hydroxycholesterol with chromatographic separation of 25-hydroxycholesterol. Anal Biochem (2008) 0.95
Inhibitory control in children with phenylketonuria. Dev Neuropsychol (2006) 0.95
Sterol metabolism disorders and neurodevelopment-an update. Dev Disabil Res Rev (2013) 0.93
Cholesterol storage defect in RSH/Smith-Lemli-Opitz syndrome fibroblasts. Mol Genet Metab (2002) 0.93
Cerebrotendinous xanthomatosis: a treatable disease with juvenile cataracts as a presenting sign. Arch Ophthalmol (2011) 0.93
Profiling sterols in cerebrotendinous xanthomatosis: utility of Girard derivatization and high resolution exact mass LC-ESI-MS(n) analysis. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 0.92
Short/branched-chain acyl-CoA dehydrogenase deficiency due to an IVS3+3A>G mutation that causes exon skipping. Hum Genet (2005) 0.92
A blood test for cerebrotendinous xanthomatosis with potential for disease detection in newborns. J Lipid Res (2013) 0.91
Assays of plasma dehydrocholesteryl esters and oxysterols from Smith-Lemli-Opitz syndrome patients. J Lipid Res (2012) 0.91
No evidence for mevalonate shunting in moderately affected children with Smith-Lemli-Opitz syndrome. J Inherit Metab Dis (2012) 0.91
Clinical and molecular features of congenital disorder of glycosylation in patients with type 1 sialotransferrin pattern and diverse ethnic origins. J Pediatr (2002) 0.91
Severe subacute GM2 gangliosidosis caused by an apparently silent HEXA mutation (V324V) that results in aberrant splicing and reduced HEXA mRNA. Am J Med Genet A (2004) 0.90
Feedback inhibition of the cholesterol biosynthetic pathway in patients with Smith-Lemli-Opitz syndrome as demonstrated by urinary mevalonate excretion. J Lipid Res (2002) 0.89
Cholesterol metabolism and suicidality in Smith-Lemli-Opitz syndrome carriers. Am J Psychiatry (2004) 0.89
Shared familial transmission of autism spectrum and attention-deficit/hyperactivity disorders. J Child Psychol Psychiatry (2014) 0.88
Potential for misdiagnosis due to lack of metabolic derangement in combined methylmalonic aciduria/hyperhomocysteinemia (cblC) in the neonate. J Perinatol (2003) 0.88
Increased nonsterol isoprenoids, dolichol and ubiquinone, in the Smith-Lemli-Opitz syndrome: effects of dietary cholesterol. J Lipid Res (2006) 0.86
Treatment of Smith-Lemli-Opitz syndrome and other sterol disorders. Am J Med Genet C Semin Med Genet (2012) 0.85
Cellular therapy for childhood neurodegenerative disease. Part II: clinical trial design and implementation. Neurosurg Focus (2008) 0.85
Rhabdomyolysis in the military: recognizing late-onset very long-chain acyl Co-A dehydrogenase deficiency. Mil Med (2006) 0.85
Clinical profile of a male with Rett syndrome. Brain Dev (2005) 0.84
Intestinal absorption of cholesterol by patients with Smith-Lemli-Opitz syndrome. Pediatr Res (2005) 0.84
Challenging behavior in Smith-Lemli-Opitz syndrome: initial test of biobehavioral influences. Cogn Behav Neurol (2013) 0.83
Executive strategic processing during verbal fluency performance in children with phenylketonuria. Child Neuropsychol (2010) 0.83
The effects of sterol structure upon sterol esterification. Atherosclerosis (2009) 0.83
Fabry disease in genetic counseling practice: recommendations of the National Society of Genetic Counselors. J Genet Couns (2002) 0.82
Mutations in γ adducin are associated with inherited cerebral palsy. Ann Neurol (2013) 0.82
Iron status of children with phenylketonuria undergoing nutrition therapy assessed by transferrin receptors. Genet Med (2004) 0.82
Postmortem screening for fatty acid oxidation disorders by analysis of Guthrie cards with tandem mass spectrometry in sudden unexpected death in infancy. J Pediatr (2002) 0.81
Alterations in membrane caveolae and BKCa channel activity in skin fibroblasts in Smith-Lemli-Opitz syndrome. Mol Genet Metab (2011) 0.80
Enhanced placental cholesterol efflux by fetal HDL in Smith-Lemli-Opitz syndrome. Mol Genet Metab (2008) 0.80
Perinatal onset mevalonate kinase deficiency. Pediatr Dev Pathol (2011) 0.79
Dietary sitostanol and campestanol: accumulation in the blood of humans with sitosterolemia and xanthomatosis and in rat tissues. Lipids (2005) 0.78
Genetics of familial hypercholesterolemia. Curr Atheroscler Rep (2015) 0.78
Processing speed and executive abilities in children with phenylketonuria. Neuropsychology (2012) 0.78
Plasma plant sterol levels do not reflect cholesterol absorption in children with Smith-Lemli-Opitz syndrome. J Pediatr (2008) 0.78
Skeletal abnormalities in lysosomal storage diseases. Pediatr Endocrinol Rev (2013) 0.78
Response monitoring in children with phenylketonuria. Neuropsychology (2009) 0.78
Tandem mass spectrometry in newborn screening: a primer for neonatal and perinatal nurses. J Perinat Neonatal Nurs (2004) 0.77
Cellular therapy for childhood neurodegenerative disease. Part I: rationale and preclinical studies. Neurosurg Focus (2008) 0.77
T cell co-stimulatory molecules: a co-conspirator in the pathogenesis of eosinophilic esophagitis? Dig Dis Sci (2013) 0.77
Lowered DHCR7 activity measured by ergosterol conversion in multiple cell types in Smith-Lemli-Opitz syndrome. Mol Genet Metab (2004) 0.77
Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev (2016) 0.77
Smith-Lemli-Opitz syndrome and inborn errors of cholesterol synthesis: summary of the 2007 SLO/RSH Foundation scientific conference sponsored by the National Institutes of Health. Genet Med (2009) 0.76
Prevalence estimation for monogenic autosomal recessive diseases using population-based genetic data. Hum Genet (2015) 0.76
Look carefully to the heels! A potentially treatable cause of spastic paraplegia. J Inherit Metab Dis (2014) 0.75
A Pilot Study of the Association of Markers of Cholesterol Synthesis with Disturbed Sleep in Smith-Lemli-Opitz Syndrome. J Dev Behav Pediatr (2016) 0.75
Expanding the limits of the Fryns syndrome. Am J Med Genet A (2003) 0.75
Prospects for stem cell therapy in neuronal ceroid lipofuscinosis. Regen Med (2013) 0.75
Metabolic disease and sudden unexpected death. J Pediatr (2003) 0.75
Breastfeeding infants with phenylketonuria in the United States and Canada. Breastfeed Med (2013) 0.75